Target intelligence / Profile preview

Hemoglobin subunit gamma-1 (HBG1)

Target
HBG1
Molecular classification
Globin, Oxygen transporter, Other (Structural component of fetal hemoglobin)
01

Overview

Hemoglobin subunit gamma-1 is one of the two gamma globin chains (the other being gamma-2, or HBG2), encoded by the HBG1 gene on chromosome 11. It is primarily expressed during fetal development in the liver, spleen, and bone marrow. Together with alpha chains, it forms fetal hemoglobin (HbF, α2γ2), which is replaced by adult hemoglobin (HbA) after birth. Unlike adult β-globin, gamma chains have greater oxygen affinity, which facilitates oxygen transfer from maternal to fetal blood. Persistence of gamma globin into adulthood (hereditary persistence of fetal hemoglobin, HPFH) or its upregulation (as in response to gene therapy or pharmacological intervention) can mitigate symptoms of beta-globin disorders such as sickle cell disease and beta-thalassemia. The protein is not a direct therapeutic target but is fundamental to clinically important biomarker and modifier gene strategies focused on increasing fetal hemoglobin for disease modification

Other names
Gamma-1-globinHb F AgammaHemoglobin gamma-1 chainHemoglobin gamma-A chainHBG-T2HBGAHBGRHSGGL1PRO2979
02

Mechanism of action

Induction of fetal hemoglobin (HbF) by stimulating HBG1 gene expression as a strategy to ameliorate symptoms in sickle cell disease and beta-thalassemia. Mechanisms include demethylation of promoters or modulation of transcription factors to maintain or reactivate gamma globin gene expression in adults

03

Biological functions

Oxygen transportHeme bindingHemoglobin alpha bindingMetal ion bindingCellular oxidant detoxificationHydrogen peroxide catabolic process
04

Disease associations

Beta-thalassemia and related hemoglobinopathiesHereditary persistence of fetal hemoglobin (HPFH)Sickle cell diseaseDelta-beta-thalassemiaFetal hemoglobin quantitative trait locusOther hemoglobin-related diseases
05

Safety considerations

No direct safety concerns tied to targeting the protein, but therapies increasing HbF may have off-target hematological effects or other complications. Overexpression in adults is generally considered benign and therapeutically beneficial
06

Interacting drugs

No direct small-molecule drugs bind hemoglobin subunit gamma-1, but drugs (e.g., hydroxyurea) and gene therapies that modulate its expression are clinically relevant in sickle cell disease and β-thalassemia treatment
07

Biomarkers

Persistence of hemoglobin subunit gamma-1 expression (HbF level) serves as a biomarker for response to therapies in beta-hemoglobinopathies and for disease prognosis in sickle cell disease and beta-thalassemia

Beyond the preview

Go deeper on Hemoglobin subunit gamma-1 (HBG1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemoglobin subunit gamma-1 (HBG1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call